drugset
drugset / Trial / NCT01084265

A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism

NCT01084265 ↗

Phase 3 Completed 31 enrolled Merck KGaA, Darmstadt, Germany Merck Pte. Ltd., Singapore · collab
NaSingle-groupOpen-labelTreatment

Summary

This was a prospective, open, non-comparative study to evaluate the safety and efficacy of recombinant human luteinizing hormone (rhLH, Luveris) administered subcutaneously (s.c.) in follicular development during ovulation induction in 31 Chinese female subjects with hypogonadotropic hypogonadism.

Timeline

Start
2004-02
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant Human Luteinizing Hormone Protein / enzyme biologic 75 iu Subcutaneous
Background Gonal-f Protein / enzyme biologic 150 iu Subcutaneous
Background human chorionic gonadotropin Protein / enzyme biologic 10000 iu —

Indications

hypogonadism